Navigation Links
Cytokinetics Reports Additional Clinical Trials Data for Ispinesib

all of these trials; patients remain on treatment in the renal cell cancer trial. Data from the other trials have already been reported.

The NCI has completed patient treatment in a Phase I clinical trial designed to evaluate the safety, tolerability and pharmacokinetics of ispinesib on an alternative dosing schedule in patients with advanced solid tumors that have failed to respond to all standard therapies; data from this trial have already been reported. The NCI is continuing patient enrollment in a Phase I clinical trial designed to evaluate the safety, tolerability and pharmacokinetics of ispinesib on an alternative dosing schedule in patients with relapsed or refractory acute leukemia, chronic myelogenous leukemia in blast crisis, or advanced myelodysplastic syndromes. Data from this trial are expected in 2007.

Background on Mitotic Kinesin Inhibitors

Since their introduction over 40 years ago, anti-mitotic drugs (taxanes and vinca alkaloids) have advanced the treatment of cancer and are commonly used for the treatment of several tumor types. However, these drugs have demonstrated limited treatment benefit against certain cancers. In addition, these drugs target tubulin, a cytoskeletal protein involved not only in mitosis and cell proliferation, but also in other important cellular functions. Inhibition of these other cellular functions produces dose-limiting toxicities such as peripheral neuropathy, an impairment of peripheral nervous system function. Neuropathies are thought to result when these drugs interfere with the dynamics of microtubule filaments that are responsible for the long-distance transport of important cellular components within nerve cells.

Mitotic kinesins are essential to mitosis, and, unlike tubulin, appear to have no role in other cellular functions. Cytokinetics believes that drugs that inhibit KSP and CENP-E and other mitotic kinesins may represent the next generation of anti-mitotic cancer drugs
'"/>




Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Cytokinetics Announces Non-clinical Data to be Presented at the 2007 AACR Annual Meeting
2. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
3. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
4. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
5. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
6. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
7. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
8. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
9. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
10. CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
11. Affymax Reports Phase 2 Clinical Dose Ranging Results of Once-Per-Month Hematide for the Treatment of Anemia
Post Your Comments:
(Date:9/17/2014)... Sept. 17, 2014  Dr. Stephen Loyd , ... House today for National Recovery Month, stars in a ... released today. Consumer advocates were also joined by a ... out after losing her fiancée because of a preventable ... had a history of crack cocaine abuse. Proposition 46 ...
(Date:9/17/2014)... , Sept. 17, 2014  Decision Resources ... (CD/UC) patients eligible for biologic therapy, only ... biologic. Surveyed gastroenterologists cite patients, discomfort with ... low penetration rates, followed by cost-related issues ... patients receiving biologics, Janssen Biotech,s Remicade and ...
(Date:9/17/2014)... Inc. announced this morning that results of the Phase 2 ... will be presented in two posters and a podium presentation ... from October 8-12. PUNCH CD study ... October 9, 2014: Poster: RBX2660 (microbiota suspension) for ... the PUNCH-CD Phase 2 Safety Study , ...
Breaking Medicine Technology:Doctor Recovering From 100-Pill-A-Day Addiction Stars In New Ad Supporting Prop 46; Appears At White House for National Recovery Month, Says Consumer Watchdog Campaign 2Doctor Recovering From 100-Pill-A-Day Addiction Stars In New Ad Supporting Prop 46; Appears At White House for National Recovery Month, Says Consumer Watchdog Campaign 3The Majority of Surveyed Gastroenterologists Agree that Biologics Should be Prescribed to More Patients in the Crohn's Disease and Ulcerative Colitis Treatment Paradigm 2The Majority of Surveyed Gastroenterologists Agree that Biologics Should be Prescribed to More Patients in the Crohn's Disease and Ulcerative Colitis Treatment Paradigm 3PUNCH CD Study Drug Targeting Recurrent C. difficile Infection to be Presented at IDWeek 2014 2PUNCH CD Study Drug Targeting Recurrent C. difficile Infection to be Presented at IDWeek 2014 3PUNCH CD Study Drug Targeting Recurrent C. difficile Infection to be Presented at IDWeek 2014 4
(Date:9/17/2014)... 17, 2014 People who struggle to distinguish ... to http://www.perwickstrom.com and get the answer by reading ... point out, is that a business plan and a business ... together, commented Per Wickstrom. “The way I view it is ... business strategy which is part two.” , According to ...
(Date:9/17/2014)... 2014 (HealthDay News) -- Social networking sites can help ... For people who are obese, sites like Twitter and ... support from doctors as well as peers, researchers found. ... methods is that it offers the potential to be ... when compared to traditional approaches," the study,s lead author, ...
(Date:9/17/2014)... Bioluminescence, nanoparticles, gene manipulation these sound like ... in fact, they are components of an exciting ... In preclinical animal models of metastatic prostate cancer, ... VCU Institute of Molecular Medicine and Johns Hopkins ... molecular imaging approach that could revolutionize doctors, ability ...
(Date:9/17/2014)... (PRWEB) September 17, 2014 North Central ... recently granted several awards for their top-notch services. The ... experience, orthopedic care and GYN surgery. , Hospital-wide, North ... Excellence Award™. They have received this award for two ... the top 5 percent in the nation for Patient ...
(Date:9/17/2014)... 2014 Catalent Pharma Solutions, the ... development solutions for drugs, biologics and consumer health ... integrated service and technology offer based on the ... the company’s 450,000 sq. ft. Kansas City, MO ... integrate optimal formulation, development, analytical expertise, scale up ...
Breaking Medicine News(10 mins):Health News:Per Wickstrom’s Latest Blog Explores the Difference Between a Business Plan and a Business Strategy 2Health News:Social Networking Sites Can Help Obese Lose Weight: Study 2Health News:New non-invasive technique could revolutionize the imaging of metastatic cancer 2Health News:New non-invasive technique could revolutionize the imaging of metastatic cancer 3Health News:North Central Surgical Center Receives Several Accolades 2Health News:New OptiPact™ Technology Introduced by Catalent 2
... ... virtual reality device, the GaitAid, can help stroke patients learn to walk better. , ... Haifa, Israel (PRWEB) February 22, 2010 -- There are ... one of the leading causes of adult disability in the U.S. and Europe., , , , ...
... new survey has found that African-Americans are more likely ... lung cancer, as well as being more reluctant to ... according to researchers from Dana-Farber Cancer Institute and their ... the puzzling racial disparities in lung cancer treatment outcomes ...
... outlets for buying booze increases, so does neighborhood violence, ... The more bars, restaurants and other alcohol sales sites ... say researchers who studied crime statistics and alcohol licensing ... found an association between high assault rates and stores ...
... three million children have been born as a result of ... tube baby" in 1978. While the majority of these ... at greater risk of certain kinds of birth defects and ... and type 2 diabetes later in life. Carmen Sapienza, ...
... types of minimally invasive surgery to repair kidney blockages ... found that robot-assisted surgery was faster and resulted in ... in the Canadian Journal of Urology , Ashok ... Baptist Medical Center, compared laparoscopic and robot-assisted surgery for ...
... 20. "Nanotechnology could aid the future of development of the ... the academy of sciences for the developing world, and president ... at a panel session, "Re-emergence of Science, Technology and Education ... AAAS,s annual meeting in San Diego. "The Arab ...
Cached Medicine News:Health News:New Successful Treatment Improves Walking Post Stroke 2Health News:African-Americans' attitudes about lung cancer may hinder prevention 2Health News:More Bars Equals More Assaults, Study Finds 2Health News:Comparison shows robot-assisted option offers advantages for kidney surgery 2Health News:Nanotechnology could help Arab region 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: